View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 19, 2021updated 11 Jul 2022 2:17pm

Moderna doses first subject in respiratory syncytial virus vaccine trial

Moderna expects to enrol nearly 34,000 subjects for the trial, which will be conducted in multiple countries.

Moderna has dosed the first subject in the Phase II/III trial of its respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The investigational single-dose mRNA vaccine candidate encodes for a prefusion F glycoprotein, eliciting a superior neutralising antibody response.

It contains optimised protein and codon sequences, as well as uses lipid nanoparticle (LNP) similar to the company’s Covid-19 vaccine.

Named ConquerRSV, the randomised, multicentre, placebo-controlled, observer-blind Phase II/III trial will be conducted in many countries.

Moderna is selecting locations of the trial depending on the ongoing RSV epidemiology and is expected to enrol nearly 34,000 subjects.

The Phase II part’s primary goal is to assess the safety of the RSV vaccine candidate in adults aged above 60 years to begin the Phase III segment.

Meanwhile, the primary purpose of the trial’s Phase III portion is to evaluate the efficacy and safety of mRNA-1345 in participants of the same age group to support licensure.

Moderna CEO Stéphane Bancel said: “We believe that the vaccine candidate against RSV can have a positive impact on public health as RSV represents a significant unmet global need.

“In addition, we believe that combination vaccines against multiple respiratory pathogens can help ensure that people are fully vaccinated by leading to higher compliance and better uptake, which may result in a longer-term benefit to healthcare systems and protect people from a broader number of respiratory viruses.”

The company recently shared interim data from a Phase I trial of the vaccine conducted in adults aged between 65 and 79 years.

It demonstrated that a single mRNA-1345 dose of 50µg, 100µg or 200µg increased neutralising antibody titers against RSV-A and RSV-B by nearly 14-fold and ten-fold, respectively.

Moderna also noted that throughout month one, a single mRNA-1345 vaccination dose of 50µg, 100µg or 200µg was found to be well-tolerated in older adults.

Furthermore, mRNA-1345 received Fast Track designation from the US Food and Drug Administration (FDA) this August for RSV in adults aged above 60 years.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena